Literature DB >> 17438339

Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.

Shen Qu1, German Perdomo, Dongming Su, Fiona M D'Souza, Neil S Shachter, H Henry Dong.   

Abstract

Apolipoprotein A-V (apoA-V) and apoC-III are exchangeable constituents of VLDL and HDL. ApoA-V counteracts the effect of apoC-III on triglyceride (TG) metabolism with poorly defined mechanisms. To better understand the effects of apoA-V on TG and cholesterol metabolism, we delivered apoA-V cDNA into livers of hypertriglyceridemic APOC3 transgenic mice by adenovirus-mediated gene transfer. In response to hepatic apoA-V production, plasma TG levels were reduced significantly as a result of enhanced VLDL catabolism without alternations in VLDL production. This effect was associated with reduced apoC-III content in VLDL. Increased apoA-V production also resulted in decreased apoC-III and increased apoA-I content in HDL. Furthermore, apoA-V-enriched HDL was associated with enhanced LCAT activity and increased cholesterol efflux. This effect, along with apoE enrichment in HDL, contributed to HDL core expansion and alpha-HDL formation, accounting for significant increases in both the number and size of HDL particles. As a result, apoA-V-treated APOC3 transgenic mice exhibited decreased VLDL-cholesterol and increased HDL-cholesterol levels. ApoA-V-mediated reduction of apoC-III content in VLDL represents an important mechanism by which apoA-V acts to ameliorate hypertriglyceridemia in adult APOC3 transgenic mice. In addition, increased apoA-V levels accounted for cholesterol redistribution from VLDL to larger HDL particles. These data suggest that in addition to its TG-lowering effect, apoA-V plays a significant role in modulating HDL maturation and cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438339      PMCID: PMC2665252          DOI: 10.1194/jlr.M600498-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  43 in total

1.  Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats.

Authors:  Hengjiang Dong; Jennifer Altomonte; Nuria Morral; Marcia Meseck; Swan N Thung; Savio L C Woo
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

2.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.

Authors:  Philippa J Talmud; Emma Hawe; Steve Martin; Michael Olivier; George J Miller; Edward M Rubin; Len A Pennacchio; Steve E Humphries
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

3.  Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.

Authors:  Len A Pennacchio; Michael Olivier; Jaroslav A Hubacek; Ronald M Krauss; Edward M Rubin; Jonathan C Cohen
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

4.  Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids.

Authors:  Bradley E Aouizerat; Medha Kulkarni; David Heilbron; Donna Drown; Stephen Raskin; Clive R Pullinger; Mary J Malloy; John P Kane
Journal:  J Lipid Res       Date:  2003-04-01       Impact factor: 5.922

5.  Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues.

Authors:  Thierry Huby; Chantal Doucet; Christiane Dachet; Betty Ouzilleau; Yukihiko Ueda; Veena Afzal; Edward Rubin; M John Chapman; Philippe Lesnik
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

Review 6.  Hypertriglyceridemia: a review beyond low-density lipoprotein.

Authors:  Richard J Rapp
Journal:  Cardiol Rev       Date:  2002 May-Jun       Impact factor: 2.644

7.  An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.

Authors:  L A Pennacchio; M Olivier; J A Hubacek; J C Cohen; D R Cox; J C Fruchart; R M Krauss; E M Rubin
Journal:  Science       Date:  2001-10-05       Impact factor: 47.728

8.  Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study.

Authors:  Paul N Hopkins; Gerardo Heiss; R Curtis Ellison; Michael A Province; James S Pankow; John H Eckfeldt; Steven C Hunt
Journal:  Circulation       Date:  2003-07-07       Impact factor: 29.690

9.  Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice.

Authors:  Jennifer Altomonte; Anja Richter; Sonal Harbaran; Jenny Suriawinata; Jun Nakae; Swan N Thung; Marcia Meseck; Domenico Accili; Hengjiang Dong
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-06-03       Impact factor: 4.310

10.  The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore.

Authors:  Chao-Qiang Lai; E-Shyong Tai; Chee Eng Tan; Jeffery Cutter; Suok Kai Chew; Yue-Ping Zhu; Xian Adiconis; Jose M Ordovas
Journal:  J Lipid Res       Date:  2003-09-01       Impact factor: 5.922

View more
  22 in total

Review 1.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

2.  Buffalo liver transcriptome analysis suggests immune tolerance as its key adaptive mechanism during early postpartum negative energy balance.

Authors:  Sudhakar Singh; Naresh Golla; Davinder Sharma; Dheer Singh; Suneel Kumar Onteru
Journal:  Funct Integr Genomics       Date:  2019-05-09       Impact factor: 3.410

Review 3.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

4.  Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.

Authors:  Anna M Blade; Melissa A Fabritius; Li Hou; Richard B Weinberg; Gregory S Shelness
Journal:  J Lipid Res       Date:  2010-11-26       Impact factor: 5.922

5.  Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.

Authors:  Xiao Shu; Lisa Nelbach; Michael M Weinstein; Braydon L Burgess; Jennifer A Beckstead; Stephen G Young; Robert O Ryan; Trudy M Forte
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-21       Impact factor: 8.311

6.  APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Xiaoyun Cheng; Jun Yamauchi; Sojin Lee; Ting Zhang; Zhenwei Gong; Radhika Muzumdar; Shen Qu; H Henry Dong
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

7.  FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Authors:  Dae Hyun Kim; Ting Zhang; Sojin Lee; Virtu Calabuig-Navarro; Jun Yamauchi; Ann Piccirillo; Yong Fan; Radha Uppala; Eric Goetzman; H Henry Dong
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

8.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

9.  Cloning and characterization of a novel apolipoprotein gene, apolipoprotein AV, in tree shrews.

Authors:  Guoping Li; Huairong Luo; Guotao Sun; Guisheng Wu; Gang Wu; Yan Wang; Yong Man; Shu Wang; Jian Li; Baosheng Chen
Journal:  Mol Biol Rep       Date:  2013-05-17       Impact factor: 2.316

10.  Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.

Authors:  Yun-Zi Liu; Xiaoyun Cheng; Ting Zhang; Sojin Lee; Jun Yamauchi; Xiangwei Xiao; George Gittes; Shen Qu; Chun-Lei Jiang; H Henry Dong
Journal:  J Biol Chem       Date:  2016-05-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.